A Feasibility Study of Neoadjuvant XELOX Without Radiotherapy for Locally Advanced Lower Rectal Cancer

Takashi Ueki, Tatsuya Manabe, Shigetaka Inoue, Jun Ienaga, Naoki Yamanaka, Takuya Egami, Mikimasa Ishikawa, Hiroyuki Konomi, Akashi Ikubo, Kinuko Nagayoshi, Masafumi Nakamura, Masao Tanaka

研究成果: Contribution to journalArticle査読

9 被引用数 (Scopus)

抄録

AIM: This study was planned to evaluate the efficacy and safety of preoperative capecitabine and oxaliplatin (XELOX) without radiation in patients with locally advanced lower rectal cancer.

PATIENTS AND METHODS: Patients with clinical stage II/III lower rectal cancer underwent three cycles of XELOX followed by radical surgery. The primary end-point was the R0 resection rate.

RESULTS: Thirty-one patients were recruited between February 2012 and August 2014. The completion rate of neoadjuvant chemotherapy was 96.5% among the 29 patients who received it; the remaining two refused chemotherapy and underwent immediate surgery. Grade 3-4 adverse events occurred in nine patients (31%). All 29 patients who received chemotherapy underwent radical resection. The R0 resection rate was 96.5% among these 29 patients. Pathological complete responses were achieved in three patients (10.3%) and downstaging occurred in 13 (44.8%).

CONCLUSION: This pilot study found that neoadjuvant XELOX for locally advanced lower rectal cancer is feasible and safe. This neoadjuvant treatment improved resection margin status.

本文言語英語
ページ(範囲)741-747
ページ数7
ジャーナルAnticancer research
36
2
出版ステータス出版済み - 2 1 2016

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

フィンガープリント 「A Feasibility Study of Neoadjuvant XELOX Without Radiotherapy for Locally Advanced Lower Rectal Cancer」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル